Free PCV, Tdap, and Varicella Vaccination Schedule Charts – PDF

Pneumococcal vaccination is administered as follows;

• Routine vaccination – PCV is a series of 4 doses administered at 2 , 4, 6 months, and between 12 and 15 months.

• Catch-up vaccination – Healthy children aged 24-59 months and with any incomplete PCV13 should receive 1 dose.

• Special situations – The following underlying conditions make up the special situations during PCV – Chronic heart disease cases (especially cyanotic congenital heart disease and cardiac failure); diabetes mellitus and chronic lung disease (which includes asthma treated with high-dose, oral corticosteroids). Vaccination should be administered as illustrated for these special situations.
  • Age 2-5 years – Any incomplete series 3 PCV13 doses should be administered with 8 weeks in between doses. If the incomplete series has less than 3 PCV13 doses, 2 doses of PCV13 should be administered at 8 weeks intervals. If the person has no history of PPSV23, 1 dose should be administered 8 weeks after all the recommended PCV13 doses have been administered.   
  • Age 6-18 years – Children with no history of PPSV23 should receive 1 dose of PPSV23, at least 8 weeks after they have received all recommended PCV13 doses.

Persons with cerebrospinal fluid leak and cochlear implant should receive PCV as follows.

• Age 2–5 years – If they have a history of any incomplete series of 3 PCV13, they should receive 1 dose PCV13 at least 8 weeks after the last PCV13 dose. If they have any incomplete series with less than 3 PCV13 doses, they should receive 2 doses of PCV13 which should be 8 weeks after the last dose and with an 8-week interval. 

• Age 6–18 years – If they have no history of either PCV13 or PPSV23, they should receive 1 dose of the PCV13 vaccine and 1 dose of PPSV23 with an 8-week interval. If they have received any PCV13 and no PPSV23, they should receive 1 dose of PPSV23 which should be given at least 8 weeks after the most recent dose of PCV13. If they have received PPSV13 but PCV13, they should receive 1 dose of PCV13, which should be given at least 8 weeks after the last dose of PPSV23.

Persons with Sickle cell disease and other hemoglobinopathies; HIV infection; solid organ transplantation; anatomic or functional asplenia; chronic renal failure; malignant neoplasms, leukemia, lymphomas, Hodgkin disease, nephrotic syndrome; congenital or acquired immunodeficiency; and other diseases related to treatment with immunosuppressive drugs or radiation therapy; multiple myeloma should receive PCV as follows;

• Age 2-5 years – Children with any incomplete series of the 3 PCV13 doses should receive 1 dose PCV13 at least 8 weeks before any previously administered PCV13 dose. If they have any incomplete series with less than 3 PCV13 doses, they should receive 2 doses of PCV13 at least 8 weeks after the most recent dose and with an interval of 8 weeks. If they have no history of PPSV23, they should receive 1 dose of PPSV23 which should be given to the person at least 8 weeks after any previously administered PCV13 dose, as well as a 2^nd dose of PPSV23 after 5 years.

• Age 6-18 years – If the person has no history of either the PCV13 or PPSV23, they should receive 1 dose of PCV13 and 2 doses of PPSV23 – 1^st dose given 8 weeks after the PCV13 and the 2^nd dose of PPSV23 5 years after the 1^st dose of PPSV23. If the person has received any PCV13 but no PPSV23, they should receive 2 doses of PPSV23 – 1^st dose given 8 weeks after the most recent PCV13 dose and the 2^nd dose of PPSV23 5 years after the 1^st dose of PCV13. If the person has had PPSV23 but no PCV13, they should receive 1 dose of PCV13 vaccine at least 8 weeks after receiving the most recent dose of PPSV23 and the 2^nd dose of PPSV23 5 years after the 1^st dose of PPSV23 at least 8 weeks after a PCV13 dose.

Persons with chronic liver disease or alcoholism should receive the vaccination as follows; if aged between 6-18 years and have no history of PPSV23, they should receive 1 dose of PPSV23 given at least 8 weeks after any previously administered PCV13 dose.

Note: Incomplete series implies that the person has not received any doses from either the endorsed series or an age-appropriate catch-up series.  

Tdap is used to protect persons from tetanus, Diphtheria, and pertussis. It should be administered as follows;

• Routine vaccination – Adolescents aged 11-12 years should be given 1 dose. Expectant mothers should get 1 dose of Tdap for each pregnancy. It is recommended that the dose be administered in the early stages of gestation (between 27-36 weeks). No interval schedules are needed when administering Tdap.

• Catch-up vaccination – Adolescents aged between 13-18 years and have not received Tdap should be given 1 dose of Tdap followed by a Td or Tdap booster vaccine every 10 years. Persons aged between 7-18 years and who have not been fully vaccinated with DTap should receive 1 dose of Tdap given as part of the catch-up vaccination series (preferably being the 1^st dose). If additional doses are to be administered, use Td or Tdap. If Tdap is administered at the age of 7-10 years, the routine Tdap dose ought to be given at 11-12 years. However, children aged 10 years do not require the routine Tdap dose.

If DTap is unintentionally administered on or after the age of 7 years, the DTap vaccine can be considered as part of the catch-up series for children aged 7-9 years, and a routine Tdap dose should be given at the age of 11-12 years. DTap dose does not count as the adolescent Tdap booster for children aged 10-18 years.     

• Special situation – wound management is recommended for persons aged 7 years or older and with a history of 3 (three) or more tetanus-toxoid-containing vaccine doses. Tdap or Td should be administered in managing clean and minor wounds for persons who received the last dose of tetanus-toxoid-containing vaccine 10 years prior. Tdap or Td should be administered for all other wounds if it’s 5 years since the person last received a tetanus-toxoid-containing vaccine dose. 

Tdap is preferably used for persons aged 11 years or older with no or unknown history of Tdap. Expectant mothers should receive Tdap if a tetanus-toxoid-containing vaccine is needed.

Note: Fully vaccinated indicates 5 valid doses of DTap or 4-DTaP valid doses if the 4^th dose was given at the age of 4 years or older.  

Varicella (chickenpox) vaccine should be administered as follows;

• Routine vaccination – The vaccine should be administered in two doses. The 1^st dose is given at the age of 12-15 months, and the 2^nd dose is given at the age of 4-6 years. The 2^nd dose may be administered to the person as early as 3 months after the 1^st dose. However, a dose administered after an interval of 4 weeks may still be counted.

• Catch-up vaccination – Persons aged 7-18 years without any evidence of immunity should get a 2-dose series of the vaccine administered as follows; if given at age 7-12 years, a routine interval of 3 months is used (doses administered at an interval of 4 weeks may be counted). Persons aged 13 years and above should receive the series with a routine interval of 4-8 weeks (the minimum interval being 4 weeks).
  The maximum age for receiving the MMRV is 12 years.

You can choose different schedules records and discuss with your doctor the one that is most suitable for your child’s health needs. Following are the free immunization sheets:

• Find the latest information on covid vaccination here.
• Find information about the other vaccine schedules here.